

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.			FIRST NAMED INVENTOR  Terry Thomas	ATTORNEY DOCKET NO. 7771-62	CONFIRMATION NO. 8090
09/822,823					
7	590	09/24/2003			
Micheline Gravelle				EXAMINER	
Bereskin & Parr Box 401			SAUNDERS, DAVID A		
40 King Street West					
Toronto, ON M5H 3Y2			ART UNIT	PAPER NUMBER	
CANADA			1644	11	
			•	DATE MAILED: 09/24/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address— **Period for Reply** A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication . - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Status This action is FINAL. ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 1 1; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4 Claim(s) \_\_ Of the above claim(s)\_\_\_\_\_ \_\_\_\_\_ is/are withdrawn from consideration. \_\_ is/are allowed. \_\_\_\_\_is/are rejected. \_ is/are objected to. ☐ Claim(s) are subject to restriction or election ☐ Claim(s)requirement. **Application Papers** ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. \_\_\_\_\_ is approved disapproved. ☐ The proposed drawing correction, filed on\_\_\_\_\_ ☐ The drawing(s) filed on\_\_\_\_\_\_ is/are objected to by the Examiner. ☐ The specification is objected to by the Examiner. ☐ The oath or declaration is objected to by the Examiner. Pri rity under 35 U.S.C. § 119 (a)-(d) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 11 9(a)-(d). ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been ☐ received. received in Application No. (Series Code/Serial Number)\_ □ received in this national stage application from the International Bureau (PCT Rule 1 7.2(a)). \*Certified copies not received:\_\_ Attachment(s) ☐ Interview Summary, PTO-413 ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). □ Notice of Informal Patent Application, PTO-152 Notice of Reference(s) Cited, PTO-892 □ Notice of Draftsperson's Patent Drawing Review, PTO-948 □ Other \_\_\_

Office Action Summary

Application/Control Number: 09/822,823

Art Unit: 1644

The amendment of 6/23/03 has been entered. Claims 21-26 are pending and under examination.

The amendment has overcome 112 and 102 rejections of record in the previous Office action.

The following 103 rejection of record is maintained.

Claims 22 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Peters et al. (FASEB J. 2000) in view of Thomas et al. (6,117,985).

The combination of references was previously applied to claims 14-20, now cancelled. Presently this combination of references is cited against new claims 23 and 26, which have incorporated the subject matter taught in the references cited previously (Paper 8).

The previously stated rejection explained how the references teach the CD45, CD 66b and CD 36 antigens were known to be on undesired cells and how they teach the glycophorin-A antigen was known to be on erythrocytes. The rejection provided motivation for combining the references.

Applicant has traversed the rejection by arguing that provisional application 60/193,371, filed 3/31/00, supports the instant claims. The examiner concurs that Table 9 from said application supports instant claims 21, 23-24 and 26; these have not been rejected claims 22 and 25, however, are not supported by application 60/193,371; there is nothing therein that points out the subcombination of these three particular antigens as being of interest. Therefore

Art Unit: 1644

the instant claims reciting this combination are not supported. As previously stated (Paper 8, page 5), original claims 15 and 18 were only granted benefit of the instant CIP filing date; Instant claims 22 and 25 correspond in content to original claims 15 and 18 and are thus presently rejected. It is noted that while Thomas et al. show CD45, CD66b and CD36 as members of a taught laundry list, rather than as a particularly preferred subcombination of these antigens, citation is proper because the claims recite "comprising".

Applicant has also urged that, even if the instant claims, were not granted benefit of the 3-31-00 filing date of application 60/193,371, the Peters et al. reference is not applicable because the disclosure therein is inventor derived. This statement (page 9) is mere a attorney pleading and not evidence. To establish derivation on the record, there must be affidavits/declarations by the other authors indicating that the relevant portions of the publication originated with, or were obtained from, the applicant.MPEP 2132.01.

Applicant's urgings filed 6/23/03 have been considered but are unconvincing of patentability.

In response to the examiner's query regarding public sale, applicant submitted a reference (Peter et al., Proceedings of the American Association for Cancer Research vol. 41, page 589, March 2000). This reference will not be cited, as was Peters et al. (FASEB Jour., April 2000), because the reference h as an authorship identical to the instant inventorship.

Application/Control Number: 09/822,823

Art Unit: 1644

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Saunders, Ph.D., whose telephone number is (703) 308-3976. The examiner can normally be reached on Monday - Thursday from 8:00 a.m. to 5:30 p.m. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan, can be reached on (703) 308-3973. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 09/822,823

Art Unit: 1644

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

D. Saunders:jmr September 10, 2003

DAVID SAUNDERS PRIMARY EXAMINER

ART UNIT 182 /644

and a Saunders